Nurix Therapeutics, Inc. (NRIX) — Institutional Holders, Q2 2026 (page 3)

213 institutional investment managers reported a NRIX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.8B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 213. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

NRIX 13F holders ranked 201–213 of 213

Institutional investors reporting a position in Nurix Therapeutics, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Caitong International Asset Management , Ltd#201 · 44 sh$1.1KNew
Covestor Ltd#202 · 31 sh$1.0K+244.4%
True Wealth Design#203 · 36 sh$874.00New
JONES FINANCIAL COMPANIES LLLP#204 · 35 sh$802.00New
Bare Financial Services#205 · 32 sh$776.00New
Fortitude Family Office#206 · 31 sh$752.000.0%
SBI Securities , Ltd.#207 · 26 sh$631.000.0%
Quarry#208 · 5 sh$121.00New
Stone House Investment Management#209 · 4 sh$97.00New
Silver Grove Financial Group#210 · 4 sh$97.00New
Hughes Financial Services#211 · 3 sh$73.000.0%
NOMURA ASSET MANAGEMENT LTD#212 · 0 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#213 · 69,327 sh—-30.0%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.